• Joseph Philip, Dalia Lopez-Colon, Ravi S Samraj, Giri Kaliki, Maria V Irwin, Biagio A Pietra, Frederick J Fricker, and Mark S Bleiweis.
• Congenital Heart Center, UFHealth Shands Children's Hospital, University of Florida, Gainesville, FL, United States. Electronic address: subijo9@ufl.edu.
• J Crit Care. 2018 Apr 1; 44: 57-62.

BackgroundThis study examines our institutional ventricular assist devices (VADs) experience over two decades to understand trends towards predictors of mortality.MethodsRetrospective study of patients aged 0-21years supported with a VAD from January 1996 to May 2015. Patient data was examined pre and post-VAD implant among survivors and non-survivors.ResultsThirty-six patients identified (8 supported by Thoratec® VAD and 28 supported by EXCOR Berlin Heart®). Patient's diagnosis included dilated cardiomyopathy (DCM) (n=19,53%), congenital heart disease (CHD) (n=12,33%), and other (n=5,14%). Median age and body surface area (BSA) were 1.0years[0-7years] and 0.41[0.24-0.92], respectively. Survival to discharge was 75% with no deaths with DCM. The survival rate for patients with CHD was 42%. Univariate analysis showed diagnosis of CHD, smaller BSA and respiratory failure post-implant (Intermacs criteria) as risk factors for mortality. Median duration of VAD support was lower in non-survivors, 14 vs 63days (p=0.03). Renal function at time of transplant or death was normal/pRIFLE Risk category in 20(74%) of survivors and 2(22%) of non-survivors (p=0.06). Post-implant, peak total bilirubin in the first week trended lower in survivors (p=0.06).ConclusionsPersistent end-organ impairment in the first 2weeks after VAD placement could be a useful prognostic marker for survival to transplant.Published by Elsevier Inc.

33 keywords...

hide…